SUSTAINED VIRAL RESPONSE AND SAFETY OF MK-7009 IN CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT

被引：1
|
作者：
Rodriguez-Torres, M. [1 ]
Stoehr, A. [2 ]
Gane, E. [3 ]
Serfaty, L. [4 ]
Lawitz, E. [5 ]
Bourque, M. [6 ,7 ]
Bhanja, S. [6 ,7 ]
Barnard, R. [6 ,7 ]
Hwang, P. [6 ,7 ]
Mobashery, N. [6 ,7 ]
机构：
[1] Fdn Invest Diego, San Juan, PR USA
[2] IFI Inst Interdisziplinare Med, Hamburg, Germany
[3] Auckland Clin Studies Ltd, Auckland, New Zealand
[4] Univ Paris 06, Serv Hepatol, Paris, France
[5] Alamo Med Res, San Antonio, TX USA
[6] Merck Sharp & Dohme Corp, West Point, PA USA
[7] Merck Sharp & Dohme Corp, N Wales, PA USA
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60108-7
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
106
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [21] Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment
    Baek, Yang Hyun
    Lee, Sung Wook
    Yoo, Hyun Seung
    Yoon, Hyun Ah
    Kim, Ja Won
    Kim, Young Hoon
    Kim, Ha Youn
    Han, Sang Young
    GUT AND LIVER, 2007, 1 (01) : 87 - 89
  • [22] Pegylated Interferon (alpha-2B) and ribavirin (Rebetol) for the treatment of HCV infected patients who failed prior therapy: Sustained response data
    Gaglio, PJ
    Choi, J
    Zimmerman, D
    Heller, L
    Brown, RS
    GASTROENTEROLOGY, 2004, 126 (04) : A721 - A721
  • [23] High sustained virological response (SVR) with pegylated interferon/ribavirin (PEG/RBV) in chronic HCV patients who have previously failed standard interferon regimes
    Wilson, J. L.
    Mellor, K.
    Campbell, B.
    Thompson, A. J. V.
    Demediuk, B.
    Shaw, G.
    Watson, K. J. R.
    Bell, S.
    Desmond, P. V.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A311 - A311
  • [24] SUSTAINED VIRAL RESPONSE (SVR) RATES IN GENOTYPE 1 TREATMENT-NAiVE PATIENTS WITH CHRONIC HEPATITIS C (CHC) INFECTION TREATED WITH VANIPREVIR (MK-7009), A NS3/4A PROTEASE INHIBITOR, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS
    Manns, Michael P.
    Gane, Edward J.
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht D.
    Yeh, Chau-Ting
    Marcellin, Patrick
    Wiedmann, Richard T.
    Hwang, Peggy
    Barnard, Richard J.
    Lee, Andrew W.
    HEPATOLOGY, 2010, 52 (04) : 361A - 361A
  • [25] Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis
    Hezode, Christophe
    Fontaine, Helene
    Dorival, Celine
    Zoulim, Fabien
    Larrey, Dominique
    Canva, Valerie
    De Ledinghen, Victor
    Poynard, Thierry
    Samuel, Didier
    Bourliere, Marc
    Alric, Laurent
    Raabe, Jean-Jacques
    Zarski, Jean-Pierre
    Marcellin, Patrick
    Riachi, Ghassan
    Bernard, Pierre-Henri
    Loustaud-Ratti, Veronique
    Chazouilleres, Olivier
    Abergel, Armand
    Guyader, Dominique
    Metivier, Sophie
    Tran, Albert
    Di Martino, Vincent
    Causse, Xavier
    Dao, Thong
    Lucidarme, Damien
    Portal, Isabelle
    Cacoub, Patrice
    Gournay, Jerome
    Grando-Lemaire, Veronique
    Hillon, Patrick
    Attali, Pierre
    Fontanges, Thierry
    Rosa, Isabelle
    Petrov-Sanchez, Ventzislava
    Barthe, Yoann
    Pawlotsky, Jean-Michel
    Pol, Stanislas
    Carrat, Fabrice
    Bronowicki, Jean-Pierre
    GASTROENTEROLOGY, 2014, 147 (01) : 132 - U235
  • [26] Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV
    Zeng, Q. -L.
    Li, C. -X.
    Zhang, D. -W.
    Li, W.
    Xu, G. -H.
    Yu, Z. -J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (07) : 842 - 843
  • [27] Favorable Outcomes of Chinese HCV-Related Cirrhotic Patients with Sustained Virological Response after Pegylated Interferon Plus Ribavirin Treatment
    Zhang, Geng-lin
    Chen, You-ming
    Zhang, Ting
    Cai, Qing-xian
    Zhang, Xiao-hong
    Zhao, Zhi-xing
    Lin, Chao-shuang
    Gao, Zhi-liang
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [28] Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naive and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection
    Ahmed, Manar
    Mansey, Azza E.
    Wahsh, Engy A.
    Gomaa, Ahmed A.
    Rabea, Hoda M.
    CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 581 - 586
  • [29] Final results of pilot study evaluating safety, viral clearance and antifibrotic efficacy of treatment with interferon γ1b+an interferon α plus ribavirin in HCV patients who failed prior pegylated interferon plus ribavirin therapy
    Balan, Vijayan
    Braaten, Julie
    Rosati, Marianne
    Williams, James
    Noble, Brie
    Anderson, Machiko
    Hentz, Joseph
    Rakela, Jorge
    Blatt, Lawrence M.
    HEPATOLOGY, 2006, 44 (04) : 611A - 611A
  • [30] The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan
    Oze, Tsugiko
    Hiramatsu, Naoki
    Yakushijin, Takayuki
    Mochizuki, Kiyoshi
    Imanaka, Kazuho
    Yamada, Akira
    Oshita, Masahide
    Kaneko, Akira
    Hagiwara, Hideki
    Mita, Eiji
    Ito, Toshifumi
    Nagase, Toshihiko
    Inui, Yoshiaki
    Hijioka, Taizo
    Tamura, Shinji
    Yoshihara, Harumasa
    Hayashi, Eijiro
    Imai, Yasuharu
    Kato, Michio
    Hosui, Atsushi
    Miyagi, Takuya
    Yoshida, Yuichi
    Ishida, Hisashi
    Tatsumi, Tomohide
    Kiso, Shinichi
    Kanto, Tatsuya
    Kasahara, Akinori
    Takehara, Tetsuo
    Hayashi, Norio
    JOURNAL OF GASTROENTEROLOGY, 2011, 46 (07) : 944 - 952
12345